九強生物(300406.SZ)在湖南設立全資子公司 註冊資本1000萬元
格隆匯9月26日丨九強生物(300406.SZ)公佈,公司利用自有資金在湖南省設立全資子公司湖南九強生物技術有限公司。近日,該子公司已經完成工商註冊登記並取得了營業執照。湖南九強生物技術有限公司成立於2022年9月23日,註冊資本1000萬元人民幣,法定代表人鄒左軍,經營範圍包括:
一般項目:生物技術推廣服務;技術服務、技術開發、技術諮詢、技術交流、技術轉讓、技術推廣;第一類醫療器械生產;第一類醫療器械銷售;第一類醫療器械租賃;第二類醫療器械銷售;第二類醫療器械租賃;醫學研究和試驗發展。(除依法須經批准的項目外,自主開展法律法規未禁止、未限制的經營活動)
許可項目:第二類醫療器械生產;第三類醫療器械生產;第三類醫療器械經營;第三類醫療器械租賃。(依法須經批准的項目,經相關部門批准後方可開展經營活動,具體經營項目以批准文件或許可證件為準)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.